InMed Pharmaceuticals gets Nasdaq equity deficiency notice
InMed Pharmaceuticals received a Nasdaq equity deficiency notice stating its shareholders’ equity is below the $2.5M minimum. The company expects to regain compliance after its planned Mentari merger.